Legend Biotech Reports Preliminary Q3 CARVYKTI Sales of ~$710M
LEGN is trading near its 52-week low of $16.24 (11% above the low).
Summary
Legend Biotech announced preliminary Q3 2026 CARVYKTI net trade sales of approximately $710 million, up from $657 million in Q2, based on unaudited data from partner Janssen.
Key Events · Earnings and Guidance · LEGN
-
Preliminary Q3 CARVYKTI Sales
CARVYKTI generated approximately $710 million in net trade sales during Q3 2026, up from $657 million in Q2 2026.
-
Sequential Growth
The $710 million figure represents roughly 8% sequential growth over Q2's $657 million, indicating continued commercial expansion.
-
Unaudited Partner Data
The sales figure is based on information provided by Janssen and has not been independently verified by Legend Biotech; final revenue and gross profit are subject to completion of Q3 financial statements.
-
Next Milestone
Final Q3 2026 financial results, including audited revenue recognition, are expected with the company's quarterly earnings release.
Analysis · LEGN · Life Sciences
CARVYKTI net trade sales reached approximately $710 million in Q3 2026, up from $657 million in Q2 — roughly 8% sequential growth. The figure is preliminary and unaudited, provided by partner Janssen, so final revenue recognition may differ. This is the first hard sales number for the quarter and confirms continued commercial momentum for the company's flagship CAR-T therapy.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LEGN was trading at $18.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $16.24 to $37.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.